Product Description
oral antibiotic (Sourced from: https://clinicaltrials.gov/ct2/history/NCT02099240?V_4=View)
Mechanisms of Action: Dihydropteroate synthase Inhibitor,CYP2C9 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Dominican Republic | Egypt | Pakistan | Taiwan | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pneumonia, Pneumocystis
Phase 1: Osteomyelitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MICU-PCP | P4 |
Unknown status |
Pneumonia, Pneumocystis |
2022-06-20 |
|
PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |